Comments Requested on Draft Second Edition FACT Standards for Immune Effector Cells
The Foundation for the Accreditation of Cellular Therapy (FACT) will publish the draft second edition FACT Standards for Immune Effector Cells on March 31, 2023, for public comment during a thirty-day period. Comments will be accepted through April 30, 2023.
These Standards promote quality practice in immune effector cell therapies and apply to a wide range of immune effector cells used to modulate an immune response for therapeutic intent, whether genetically modified or not. This includes, but is not limited to, dendritic cells, natural killer cells, T cells, B cells, genetically engineered chimeric antigen receptor T cells (CAR-T cells), and therapeutic vaccines. The final Standards will be published in November 2023 and will become effective in February 2024.
The FACT Standards for Immune Effector Cells were reviewed and commented upon during an initial public comment period in association with the eighth edition FACT-JACIE International Standards for Hematopoietic Cellular Therapy Product Collection, Processing, and Administration. The majority of comments received have been addressed through harmonizing these two publications.
Comments submitted during the first comment period clearly indicated a need to enhance standards related to cell collection. These comments have been addressed in B2.12, B2.12.1, and in a reorganized Section C that now includes general standards applicable to any cell collection followed by sections C9, C10, and C11 specific to apheresis and whole blood collection, marrow collection, and collection of other tissues such as tumor-infiltrating lymphocytes (TILs).
The purpose of this comment period will be to specifically request your comments on these new sections. Two versions of the published draft are available. One is a clean version, and the other is a redline document intended to highlight the changes made to these Standards. Minor reorganization and clarifying changes are not tracked. Some changes are new standards; however, some are intended to clarify rather than to change the intent. In addition, many changes were made to provide consistency among all sets of FACT Standards:
- Draft Second Edition FACT Immune Effector Cells Standards
- Draft IEC Redlined Document
- Visit the FACT IEC RedCap Survey for instructions and to submit your comments
If you have any questions, please contact Monique Summers, FACT Standards Development Manager at monique.summers@factglobal.org or 402-920-7010.
IEC Webinar Series: Solid Tumors
General Concepts and Need for Harmonization of Standards
September 28, 2022
Join us on Wednesday, September 28, 2022, at 11:00 am ET/15:00 GMT, for the FACT IEC Webinar: General Concepts and Need for Harmonization of Standards. Basem William, MD, MRCP, FACP, from Ohio Health Blood and Marrow Transplant and Cellular Therapy Program, and Sarah Nikiforow, MD, PhD, from Dana-Farber Cancer Institute / Cell Manipulation Core Facility, will discuss the following:
- Introduction to IEC in solid tumors
- Unique challenges with IEC in solid tumors
- Subtypes of IEC in solid tumors; TIL, CAR-T, TCR, others
- Unique consideration in solid tumor IEC manufacturing
- Need for harmonization of IEC standards; how FACT can help
Tumor Infiltrating Lymphocytes
January 17, 2023
Join us on Tuesday, January 17, 2023, at 11:00 am ET/16:00 GMT, for the FACT IEC Webinar: Tumor Infiltrating Lymphocytes. Parameswaran Hari, MD, MRCP, DRCPath, MS, from Iovance Biotherapeutics, and John Mullinax, MD, from H. Lee Moffitt Cancer Center & Research Institute Blood and Marrow Transplant Program, will discuss the following:
- Introduction to TIL therapy?
- Review of current clinical experience with TIL
- Unique consideration in TIL manufacturing
- Need for establishing safety and efficacy quality benchmarks for TIL; how FACT can help
Other webinars in this series include:
CAR-T Cells and T-Cell Receptor Cells (TCR) in Solid Tumors (Date TBD)
